BrahMos WORLD INDIA MADHYA PRADESH BHOPAL WTN SPECIAL GOSSIP CORNER RELIGION SPORTS BUSINESS FUN FACTS ENTERTAINMENT LIFESTYLE TRAVEL ART & LITERATURE SCIENCE & TECHNOLOGY HEALTH EDUCATION DIASPORA OPINION & INTERVIEW RECIPES DRINKS BIG MEMSAAB 2017 BUDGET 2017 FUNNY VIDEOS VIRAL ON WEB PICTURE STORIES Mahakal Ke Darshan
WTN HINDI ABOUT US PRIVACY POLICY SITEMAP CONTACT US
logo
Breaking News

Novel drug may provide hope for blood cancer patients

Saturday - June 10, 2017 3:40 pm , Category : DIASPORA
 Novel drug may provide hope for blood cancer patients
Novel drug may provide hope for blood cancer patients

New York June 10 (IANS) A team led by an Indian-origin researcher has discovered a new drug that could alone or combined with chemotherapy provide better treatment for patients with blood cancer.

Lymphoblastic leukemia or ALL is the most common form of cancer in children but also affects adults and is characterised by an overproduction of immature white blood cells and lesser red blood cells.

Scientists have found up to 30 per cent of adult ALL patients have a Philadelphia chromosome which are addicted to repairing DNA.

Thus they focussed on two specific proteins that were directly involved in DNA repair called histone deacetylases (HDAC) 1 and 2 and developed a drug that inhibits their activity.

The drugs broke down the central hub of DNA repair and the HDAC 1 2 inhibitor actually reduced different repair protein functions.

In this study led by Srividya Bhaskara Assistant Professor at the University of Utah when mice were treated with the HDAC 1 2 inhibitor or the combination of HDAC1 2 and doxorubicin -- the chemotherapy drug -- their bone marrow started turning from pale to red indicating the white blood cells were being replaced with red blood cells.

A 50-70 per cent reduction in leukemia was observed with either HDAC1 2 inhibitor alone or when the inhibitor was used with doxorubicin a decrease that can give a patient several more years of survival the researchers said in the paper reported in the journal Leukemia.

We completely nailed down how the HDAC1 2 inhibitor affects DNA repair. This is so important not just for this cancer but any cancer that is repair-addicted Bhaskara stated.

Further no side effect of the treatment was seen in mice.

The next steps will include initiating human clinical trials the researchers said.

--IANS
rt/ruwa/bg